Is HealthEquity (HQY) Undervalued On Fresh Growth Stock Support?
A fresh note from the Zacks Growth Style Score system has pushed HealthEquity (HQY) onto growth investors’ radar, highlighting projected outperformance in both earnings per share and cash flow compared with the broader industry.
Recent trading has been choppy for HealthEquity, with the share price slipping 2.77% in the last session even after a 14.31% 1 month share price return and a 10.77% share price gain year to date. That sits alongside a 6.02% 1 year total shareholder return and a 40.74% 3 year total shareholder return, which indicates momentum that has cooled in the short term while remaining positive over a multi year period as investors weigh growth signals from earnings and cash flow forecasts against pockets of profit taking.
Scan beyond HealthEquity and size up other potential growth stories with the hand picked 21 high quality undiscovered gems that are already posting solid fundamentals but still fly under most investors’ radar.
Bulls point to HealthEquity’s growth credentials and implied discount, while bears see a hot chart that has started to cool. Which side does the current valuation really lean toward?
Most Popular Narrative: 15.5% Undervalued
On the most followed framework, HealthEquity’s estimated fair value of $119.33 sits above the recent $100.88 close, which puts the focus squarely on how earnings quality and cash generation support that gap.
The recent regulatory expansion that allows direct primary care, pre-deductible telehealth and new ACA Bronze and catastrophic plan members to qualify for HSAs continues to enlarge HealthEquity’s addressable market. This can feed future HSA account and asset growth and support revenue.
See why 6 investors see HealthEquity as 15% undervalued.
Result: Fair Value of $119.33 (UNDERVALUED)
Still, the HealthEquity story can be knocked off course if employer driven HSA sign ups slow, or if administration fee pressure squeezes service revenue and margins.
Find out about the key risks to this HealthEquity narrative.
Another Take on HealthEquity’s Valuation
On price based measures, HealthEquity looks punchy. The stock trades on a P/E of 35.3x, while peers trade around 31.2x, the wider US Healthcare group is at 25.6x, and the fair ratio is 26.1x. That points to a premium valuation. Is the growth story strong enough to keep investors comfortable with that gap?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the HealthEquity debate feels finely balanced, do not wait for consensus. Pull apart the numbers yourself, weigh the optimism and pressure points, then see how others frame those 1 or more potential upsides through the 3 key rewards.
Looking For More Investment Ideas Beyond HealthEquity?
Do not stop with HealthEquity. Give yourself options by lining up fresh ideas from different corners of the market so you can compare quality, income and resilience.
- Target income by reviewing a shortlist of higher yielding payers screened for resilience through the 5 dividend fortresses.
- Look for potentially mispriced opportunities by scanning companies that combine quality fundamentals with specific valuation characteristics via the 29 high quality undervalued stocks.
- Emphasize capital preservation by focusing on businesses filtered using the 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com